retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset From Obesity to Metabolic Health:

This included a less than 5% incidence rate of gastrointestinal adverse events and zero neuropsychiatric adverse events, which have been an issue with small-molecule CB1 inhibitors that have greater activity in the central nervous system

Easy to take

Researchers have already tested a range of doses and escalation schedules, providing valuable insight into how treatment may start, increase, and be maintained

The GLP1 Surge Experts widely agree that the modest nationwide weight-loss trend so far stems from the pharmacological innovation of GLP1 drugs, not health policy

The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimers disease

This warning is based on findings in rodent studies where these drugs caused thyroid C-cell tumors (medullary thyroid carcinoma) at clinically relevant exposures